C
알지노믹스
476830KOSDAQ48.5 / 100
Reference Date: 2026-10-23
Financial Score20.0 / 40
News Sentiment12.5 / 25
Momentum6.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Declined 5.7% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Aljonoomics is a biotech company that develops new drugs using platform technology, leveraging RNA trans-splicing ribozyme to target and replace specific RNA sequences with therapeutic genes. The company generates revenue through technology licensing and focuses on developing gene therapy treatments for genetic diseases and cancer, including hepatocellular carcinoma.
Number of Employees
39people
Average Salary
193.2M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
11.77Industry Average 1.200.0Point
9.8x industry avg (risky)
ROE
—Industry Average 8.003.5Point
Debt Ratio
1.62Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20254.5 / 10 points
Revenue Growth Rate
1.5 / 3
Operating Profit Growth Rate
1.0 / 3
Avg ▲1.8% (2-year basis)
ROE Trend
2.0 / 4
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (2%, downtrend)
Current 24,700Won52-week high 236,00052-week low 20,150
1-month return2.0Point
1m -5.73% (slight drop)
Volume trend3.0Point
Volume flat
Detailed Disclosure
4 totalPositive 0Neutral 4Negative 0
- Neutral주식등의대량보유상황보고서(일반)2026-10-15
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-08
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-08
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-08